Research evaluating immune checkpoints may help identify those likely to benefit from PD-1/PD-L1 immunotherapy and reveal new immunotherapy targets for future investigation. See how the MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 2 was used to multiplex immune checkpoint molecules for